• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Bicara Therapeutics Inc. - Common Stock (NQ:BCAX)

    27.99 +0.39 (+1.40%)
    Streaming Delayed Price Updated: 10:35 AM EDT, Jul 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Bicara Therapeutics Inc. - Common Stock

    < Previous 1 2 3 Next >
    News headline image
    Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
     
    Via Benzinga
    News headline image
    Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket ↗
     
    Via Benzinga
    News headline image
    BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    This Wells Fargo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
     
    Via Benzinga
    News headline image
    This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
     
    Via Benzinga
    News headline image
    StandardAero Surges In Market Debut ↗
    Shares of StandardAero jumped 36% in the company's trading debut as the aircraft maintenance services provider raised $1.44 billion in its IPO. Additionally, Chain Bridge Bancorp opened on Oct. 5 at... 
    Via Talk Markets
    Topics Initial Public Offering
    News headline image
    Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Trio Of Biotech IPOs Climb In Debut ↗
    A trio of biotech companies' shares rose on Friday in their first trading sessions. Bicara Therapeutics, MBX Biosciences, and Zenas BioPharma each sold more shares in their respective initial public... 
    Via Talk Markets
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.